Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2221–34

European Urology 2026

View at publisher

Authors: Tyler S. Garman, Max R. Kates

DOI: 10.1016/j.eururo.2026.01.010

Cited by: 0

References: 4

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers Urinary Bladder and Prostate Research

References 4